Research
/
Stock
/
NVS
N
NVS
NOVARTIS AG
FY2025
i
USD → USD approx
Dual-class
159.98
+1.96 +1.24%
close 2026-08-25
i
Overview
Financials
Insider
DCF
Research
/
Stock
/
…
Pulling SEC filings & building this page… the first lookup of a new ticker takes a few seconds, then it's cached.
Mkt Cap
i
—
P/E
i
—
Revenue FY2025
i
—
Gross Margin
i
—
FCF FY2025
i
—
Net Income
i
14.0B
52-week range
i
118.20
-2.2% off high
i
163.64
Beta
i
0.32
vs S&P 500 · 1254 common days
Dividend
i
—
no dividend line in the cash flow statement
Price
i
1M
6M
1Y
5Y
i
i
Revenue
i
—
FY2025
i
·
—
i
i
EBITDA
i
—
not reported
Free Cash Flow
i
—
FY2025
i
·
—
i
i
EPS (diluted)
i
—
FY2025
i
·
—
i
i
Earnings
i
next est.
Last reported
4 Feb 2026 · 20-F
Next report
≈ 5 Feb 2027
Moat & Risks
i
Engine pending
Sourced moat / risk brief — generated by the Silkcodex engine (pending run).
Insider activity
i
12 Form 4 · 1 open-market buy vs 8 sells
i
All transactions →
−6M
net open-market
i
2020-07-14
C
Novartis Pharma Ag
· 10% owner
Conversion
5,908,089
—
2020-06-30
C
Novartis Bioventures Ltd
Conversion
856,262
—
2020-06-30
C
Novartis Bioventures Ltd
Conversion
199,996
—
2020-06-30
P
Novartis Bioventures Ltd
Buy
125,000
2M
2020-06-19
S
Novartis Bioventures Ltd
Sell
1,001,312
8M
Recent filings
8 on file · SEC EDGAR
i
2026-07-21
6-K
Foreign interim report
EDGAR ›
2026-06-11
6-K
Foreign interim report
EDGAR ›
2026-04-28
6-K
Foreign interim report
EDGAR ›
2026-03-18
6-K
Foreign interim report
EDGAR ›
2026-02-04
6-K
Foreign interim report
EDGAR ›